Document Classification

Section Type: RESULTS

Text: At the end of the follow-up period, patients in the nateglinide group (n = 55), compared to patients in the placebo group (n = 54), showed lower values of HbA1c (6. 7 + / - 0. 6 vs. 7. 2 + / - 0. 7 %, respectively ; P < 0. 001), fasting plasma glucose (7. 9 + / - 2. 1 vs. 8. 5 + / - 2. 0 mmol L (-1) ; P = 0. 023) and systolic blood pressure (125. 3 + / - 15. 4 vs. 129. 3 + / - 18. 7 mmHg ; P = 0. 015), and higher values of HOMA-B % [75. 7 (51. 8-99. 4) vs. 57. 7 (42. 2-83. 4) ; P = 0. 033].